- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523064
iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump (POST-CABGDM)
SGLT2 Inhibitors in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Random Prospective Study non-blinded with 144 diabetics patients designated to myocardial revascularization with cardiopulmonary bypass . 72 patients will be randomly set to usual treatment provided by health care service and 72 patients will be randomly assigned treatment based on ISGLT2 (Empaglifozin). Patients will receive treatment as set for 3 months until 3 days prior to surgery. Creatinine levels will be measured immediately after surgery and in the following 3 days in post-op.
To evaluate the possibility to reduce the acute kidney injury in a randomized group treated with therapy based on ISGLT2.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Carlos V Serrano, MD, PhD
- Phone Number: +551126615241
- Email: cvserranojr@gmail.com
Study Contact Backup
- Name: Simone Souza
- Phone Number: +551126615241
- Email: simone.souza@incor.usp.br
Study Locations
-
-
SP
-
Sao Paulo, SP, Brazil, 05403010
- Recruiting
- University of Sao Paulo Medical School - The Heart Institute
-
Sub-Investigator:
- José Otávio C Auler Jr, MD, PHD
-
Contact:
- Fabio G Pitta, M.D.
- Phone Number: +5511991784180
- Email: fgpitta@gmail.com
-
Contact:
- Simone Souza
- Phone Number: +551126615352
- Email: simone.souza@incor.usp.br
-
Sub-Investigator:
- Fabio G Pitta, MD
-
Principal Investigator:
- Eduardo G Lima, MD, PhD
-
Sub-Investigator:
- Luis Antonio M Cesar, MD, PhD
-
Sub-Investigator:
- Luis A Dallan, MD, PHD
-
Sub-Investigator:
- Celia Strunz, MD, PhD
-
Sub-Investigator:
- Paula Bolta, MsC
-
Sub-Investigator:
- Eduardo M Moreira, MD
-
Principal Investigator:
- Carlos V Serrano Jr., MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18
- Type 2 diabetes mellitus
- Multivessel CAD documented by coronary angiography with formal indication for CRM.
Exclusion Criteria:
- eGFR <30mL / min / 1.73m2 or dialysis therapy;
- Inability to sign the informed consent form;
- Contraindication to CABG on pump;
- Need for urgent or emergency CABG;
- Terminal or disabling illness with reduced life expectancy;
- Pregnancy in progress.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SGLT2i (empagliflozin)
Empagliflozin 25 mg 1 time day for three months
|
Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
Other Names:
|
No Intervention: Standard of care
Standard care treatment of diabetes patients in our center
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute kidney injury
Time Frame: 3 months
|
Development of post-CABG acute kidney injury according to RIFFLE or AKIN or KDIGO criteria
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Atrial fibrillation
Time Frame: 3 months
|
Development of atrial fibrillation during hospital admission
|
3 months
|
Pulmonary infection
Time Frame: 3 months
|
Development of pulmonary infection during hospital admission
|
3 months
|
Infection of surgical site
Time Frame: 3 months
|
Development of infection of surgical site during hospital admission
|
3 months
|
ICU readmission
Time Frame: 3 months
|
Transfer to ICU during hospital admission
|
3 months
|
Need for IV insulin
Time Frame: 3 months
|
Need for IV insulin during hospital admission
|
3 months
|
Myocardial Infarction Type 5
Time Frame: 3 months
|
Occurence of myocardial infarction type 5 during admission
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Carlos V Serrano, MD, PhD, Instituto do Coração - Hospital das Clinicas FMUSP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Renal Insufficiency
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Wounds and Injuries
- Acute Kidney Injury
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Empagliflozin
Other Study ID Numbers
- 4957/19/176
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Empagliflozin 25 MG
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
National Taiwan University HospitalShin Kong Wu Ho-Su Memorial HospitalNot yet recruitingHeart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Amsterdam UMC, location VUmcCompleted
-
Yale UniversityBoehringer IngelheimRecruitingEnd Stage Renal Disease on DialysisUnited States
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
University Health Network, TorontoRecruiting
-
Tanta UniversityActive, not recruiting
-
Isfahan University of Medical SciencesCompletedDiabetes MellitusIran, Islamic Republic of
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Doris...RecruitingType2 Diabetes | Heart Failure With Preserved Ejection FractionUnited States